AMICUS THERAPEUTICS INC's ticker is FOLD and the CUSIP is 03152W109. A total of 277 filers reported holding AMICUS THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 0.99 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $524 | -1.9% | 43,094 | +1.4% | 0.00% | 0.0% |
| Q2 2023 | $534 | +23.0% | 42,492 | +8.7% | 0.00% | 0.0% |
| Q1 2023 | $434 | -21.9% | 39,092 | -14.1% | 0.00% | -20.0% |
| Q4 2022 | $556 | -99.9% | 45,518 | +2.0% | 0.01% | +25.0% |
| Q3 2022 | $466,000 | -0.4% | 44,619 | +2.4% | 0.00% | 0.0% |
| Q2 2022 | $468,000 | +14.7% | 43,559 | +1.2% | 0.00% | +33.3% |
| Q1 2022 | $408,000 | -61.9% | 43,048 | -53.5% | 0.00% | -25.0% |
| Q4 2021 | $1,070,000 | +139.4% | 92,556 | +97.9% | 0.00% | 0.0% |
| Q3 2021 | $447,000 | -6.7% | 46,780 | -5.8% | 0.00% | 0.0% |
| Q2 2021 | $479,000 | +32.3% | 49,661 | +35.7% | 0.00% | -71.4% |
| Q1 2021 | $362,000 | -61.0% | 36,609 | -8.9% | 0.01% | -60.0% |
| Q4 2020 | $928,000 | +66.3% | 40,185 | +1.6% | 0.04% | +45.8% |
| Q3 2020 | $558,000 | -9.1% | 39,538 | -2.8% | 0.02% | -14.3% |
| Q2 2020 | $614,000 | +50.5% | 40,697 | -7.8% | 0.03% | +180.0% |
| Q1 2020 | $408,000 | -7.9% | 44,118 | -3.1% | 0.01% | +25.0% |
| Q4 2019 | $443,000 | +34.7% | 45,506 | +10.8% | 0.01% | +14.3% |
| Q3 2019 | $329,000 | -36.7% | 41,055 | -1.4% | 0.01% | -41.7% |
| Q2 2019 | $520,000 | +32.7% | 41,636 | +44.6% | 0.01% | +33.3% |
| Q1 2019 | $392,000 | +47.9% | 28,789 | +4.3% | 0.01% | +12.5% |
| Q4 2018 | $265,000 | +97.8% | 27,615 | +149.6% | 0.01% | +166.7% |
| Q3 2018 | $134,000 | -70.3% | 11,065 | -61.7% | 0.00% | -72.7% |
| Q2 2018 | $451,000 | +20.6% | 28,896 | +16.1% | 0.01% | +10.0% |
| Q1 2018 | $374,000 | +14.0% | 24,885 | +9.3% | 0.01% | +11.1% |
| Q4 2017 | $328,000 | +3.5% | 22,766 | +8.3% | 0.01% | -10.0% |
| Q3 2017 | $317,000 | +70.4% | 21,017 | +13.9% | 0.01% | +66.7% |
| Q2 2017 | $186,000 | +50.0% | 18,451 | +5.7% | 0.01% | 0.0% |
| Q1 2017 | $124,000 | +42.5% | 17,449 | -0.2% | 0.01% | +50.0% |
| Q4 2016 | $87,000 | -20.9% | 17,479 | +18.0% | 0.00% | -33.3% |
| Q3 2016 | $110,000 | +22.2% | 14,818 | +10.1% | 0.01% | +20.0% |
| Q2 2016 | $90,000 | -12.6% | 13,453 | +10.1% | 0.01% | -50.0% |
| Q1 2016 | $103,000 | -4.6% | 12,215 | +9.8% | 0.01% | -23.1% |
| Q4 2015 | $108,000 | -36.5% | 11,120 | -8.6% | 0.01% | -27.8% |
| Q3 2015 | $170,000 | – | 12,160 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Palo Alto Investors LP | 10,524,022 | $127,972,108 | 12.11% |
| Perceptive Advisors | 27,692,917 | $336,745,870 | 11.23% |
| Redmile Group, LLC | 16,944,621 | $206,046,591 | 9.80% |
| Finepoint Capital LP | 1,489,025 | $18,106,544 | 9.02% |
| CM Management, LLC | 450,000 | $5,472,000 | 5.81% |
| Avoro Capital Advisors LLC | 27,400,000 | $333,184,000 | 5.20% |
| MPM BioImpact LLC | 716,139 | $8,708,250 | 2.32% |
| Artal Group S.A. | 4,062,567 | $49,401 | 2.12% |
| SECTORAL ASSET MANAGEMENT INC | 803,464 | $9,770,122 | 1.90% |
| GREAT POINT PARTNERS LLC | 857,000 | $10,421,120 | 1.90% |